Association between a Specific Apolipoprotein B Mutation and Familial Defective Apolipoprotein B-100

Familial defective apolipoprotein (apo) B-100 is a genetic disease that leads to hypercholesterolemia and to an increased serum concentration of low density lipoproteins that bind defectively to the apoB,E(LDL) receptor. The disorder appears to result from a mutation in the gene for apoB-100. Extens...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 86; no. 2; pp. 587 - 591
Main Authors Soria, Luis F., Ludwig, Erwin H., Howard R. G. Clarke, Vega, Gloria L., Grundy, Scott M., McCarthy, Brian J.
Format Journal Article
LanguageEnglish
Published Washington, DC National Academy of Sciences of the United States of America 01.01.1989
National Acad Sciences
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Familial defective apolipoprotein (apo) B-100 is a genetic disease that leads to hypercholesterolemia and to an increased serum concentration of low density lipoproteins that bind defectively to the apoB,E(LDL) receptor. The disorder appears to result from a mutation in the gene for apoB-100. Extensive sequence analysis of the two alleles of one subject heterozygous for the disorder has revealed a previously unreported mutation in the codon for amino acid 3500 that results in the substitution of glutamine for arginine. This same mutant allele occurs in six other, unrelated subjects and in eight affected relatives in two of these families. A partial haplotype of this mutant apoB-100 allele was constructed by sequence analysis and restriction enzyme digestion at positions where variations in the apoB-100 are known to occur. This haplotype is the same in three probands and four affected members of one family and lacks a polymorphic Xba I site whose presence has been correlated with high cholesterol levels. Thus, it appears that the mutation in the codon for amino acid 3500 (CGG → CAG), a CG mutational ``hot spot,'' defines a minor apoB-100 allele associated with defective low density lipoproteins and hypercholesterolemia.
AbstractList Familial defective apolipoprotein (apo) B-100 is a genetic disease that leads to hypercholesterolemia and to an increased serum concentration of low density lipoproteins that bind defectively to the apoB,E(LDL) receptor. The disorder appears to result from a mutation in the gene for apoB-100. Extensive sequence analysis of the two alleles of one subject heterozygous for the disorder has revealed a previously unreported mutation in the codon for amino acid 3500 that results in the substitution of glutamine for arginine. This same mutant allele occurs in six other, unrelated subjects and in eight affected relatives in two of these families. A partial haplotype of this mutant apoB-100 allele was constructed by sequence analysis and restriction enzyme digestion at positions where variations in the apoB-100 are known to occur. This haplotype is the same in three probands and four affected members of one family and lacks a polymorphic Xba I site whose presence has been correlated with high cholesterol levels. Thus, it appears that the mutation in the codon for amino acid 3500 (CGG---CAG), a CG mutational "hot spot," defines a minor apoB-100 allele associated with defective low density lipoproteins and hypercholesterolemia.
Familial defective apolipoprotein (apo) B-100 is a genetic disease that leads to hypercholesterolemia and to an increased serum concentration of low density lipoproteins that bind defectively to the apoB,E(LDL) receptor. The disorder appears to result from a mutation in the gene for apoB-100. Extensive sequence analysis of the two alleles of one subject heterozygous for the disorder has revealed a previously unreported mutation in the codon for amino acid 3500 that results in the substitution of glutamine for arginine. This same mutant allele occurs in six other, unrelated subjects and in eight affected relatives in two of these families. It appears that the mutation in the codon for amino acid 3500 (CGG arrow right CAG), a CG mutational "hot spot," defines a minor apoB-100 allele associated with defective low density lipoproteins and hypercholesterolemia.
Familial defective apolipoprotein (apo) B-100 is a genetic disease that leads to hypercholesterolemia and to an increased serum concentration of low density lipoproteins that bind defectively to the apoB,E(LDL) receptor. The disorder appears to result from a mutation in the gene for apoB-100. Extensive sequence analysis of the two alleles of one subject heterozygous for the disorder has revealed a previously unreported mutation in the codon for amino acid 3500 that results in the substitution of glutamine for arginine. This same mutant allele occurs in six other, unrelated subjects and in eight affected relatives in two of these families. A partial haplotype of this mutant apoB-100 allele was constructed by sequence analysis and restriction enzyme digestion at positions where variations in the apoB-100 are known to occur. This haplotype is the same in three probands and four affected members of one family and lacks a polymorphic Xba I site whose presence has been correlated with high cholesterol levels. Thus, it appears that the mutation in the codon for amino acid 3500 (CGG → CAG), a CG mutational ``hot spot,'' defines a minor apoB-100 allele associated with defective low density lipoproteins and hypercholesterolemia.
Familial defective apolipoprotein (apo) B-100 is a genetic disease that leads to hypercholesterolemia and to an increased serum concentration of low density lipoproteins that bind defectively to the apoB,E(LDL) receptor. The disorder appears to result from a mutation in the gene for apoB-100. Extensive sequence analysis of the two alleles of one subject heterozygous for the disorder has revealed a previously unreported mutation in the codon for amino acid 3500 that results in the substitution of glutamine for arginine. This same mutant allele occurs in six other, unrelated subjects and in eight affected relatives in two of these families. A partial haplotype of this mutant apoB-100 allele was constructed by sequence analysis and restriction enzyme digestion at positions where variations in the apoB-100 are known to occur. This haplotype is the same in three probands and four affected members of one family and lacks a polymorphic Xba I site whose presence has been correlated with high cholesterol levels. Thus, it appears that the mutation in the codon for amino acid 3500 (CGG {yields} CAG), a CG mutational hot spot, defines a minor apoB-100 allele associated with defective low density lipoproteins and hypercholesterolemia.
Familial defective apolipoprotein (apo) B-100 is a genetic disease that leads to hypercholesterolemia and to an increased serum concentration of low density lipoproteins that bind defectively to the apoB,E(LDL) receptor. The disorder appears to result from a mutation in the gene for apoB-100. Extensive sequence analysis of the two alleles of one subject heterozygous for the disorder has revealed a previously unreported mutation in the codon for amino acid 3500 that results in the substitution of glutamine for arginine. This same mutant allele occurs in six other, unrelated subjects and in eight affected relatives in two of these families. A partial haplotype of this mutant apoB-100 allele was constructed by sequence analysis and restriction enzyme digestion at positions where variations in the apoB-100 are known to occur. This haplotype is the same in three probands and four affected members of one family and lacks a polymorphic Xba I site whose presence has been correlated with high cholesterol levels. Thus, it appears that the mutation in the codon for amino acid 3500 (CGG---CAG), a CG mutational "hot spot," defines a minor apoB-100 allele associated with defective low density lipoproteins and hypercholesterolemia.Familial defective apolipoprotein (apo) B-100 is a genetic disease that leads to hypercholesterolemia and to an increased serum concentration of low density lipoproteins that bind defectively to the apoB,E(LDL) receptor. The disorder appears to result from a mutation in the gene for apoB-100. Extensive sequence analysis of the two alleles of one subject heterozygous for the disorder has revealed a previously unreported mutation in the codon for amino acid 3500 that results in the substitution of glutamine for arginine. This same mutant allele occurs in six other, unrelated subjects and in eight affected relatives in two of these families. A partial haplotype of this mutant apoB-100 allele was constructed by sequence analysis and restriction enzyme digestion at positions where variations in the apoB-100 are known to occur. This haplotype is the same in three probands and four affected members of one family and lacks a polymorphic Xba I site whose presence has been correlated with high cholesterol levels. Thus, it appears that the mutation in the codon for amino acid 3500 (CGG---CAG), a CG mutational "hot spot," defines a minor apoB-100 allele associated with defective low density lipoproteins and hypercholesterolemia.
Author Vega, Gloria L.
Soria, Luis F.
McCarthy, Brian J.
Howard R. G. Clarke
Ludwig, Erwin H.
Grundy, Scott M.
AuthorAffiliation Gladstone Foundation Laboratories for Cardiovascular Disease, University of California, San Francisco 94140-0608
AuthorAffiliation_xml – name: Gladstone Foundation Laboratories for Cardiovascular Disease, University of California, San Francisco 94140-0608
Author_xml – sequence: 1
  givenname: Luis F.
  surname: Soria
  fullname: Soria, Luis F.
– sequence: 2
  givenname: Erwin H.
  surname: Ludwig
  fullname: Ludwig, Erwin H.
– sequence: 3
  fullname: Howard R. G. Clarke
– sequence: 4
  givenname: Gloria L.
  surname: Vega
  fullname: Vega, Gloria L.
– sequence: 5
  givenname: Scott M.
  surname: Grundy
  fullname: Grundy, Scott M.
– sequence: 6
  givenname: Brian J.
  surname: McCarthy
  fullname: McCarthy, Brian J.
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=6868848$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/2563166$$D View this record in MEDLINE/PubMed
https://www.osti.gov/biblio/7018777$$D View this record in Osti.gov
BookMark eNqFks1v1DAQxS1UVLYLRy4IpAgBtyz-iD9y4LC0FJCKOABny3Fs6sprp7G3wH-Pt0lXBQScLPn93swbzRyBgxCDAeAhgisEOXk5BJVWgq3wigp-BywQbFHNmhYegAWEmNeiwc09cJTSBYSwpQIegkNMGUGMLUC_Tilqp7KLoepM_mZMqFT1aTDaWaer9RC9G-IwxmxcqF5XH7Z5glXoq1O1cd4pX50Ya3R2V-YPQ40gvA_uWuWTeTC_S_Dl9M3n43f12ce374_XZ7VmsMk1Q521kBBjO2I71uqeUq16iBhEnCBNqGK46bvWKN4IZQmhENO-pZ2g2HY9WYJXU91h221Mr03Io_JyGN1GjT9kVE7-qgR3Lr_GK4kFo6XFEjyd_DFlJ5N22ehzHUMos0kOkeB8B72Ym4zxcmtSlhuXtPFeBRO3SXIhGo5J-18QUc7LflgBn9yOvc87L6noz2ZdJa28HVXQLu0xJlhpKQpGJkyPMaXRWFkGuN5VmdV5iaDcHYzcHYwUTGJZDqa46t9cN3X_xj-ew-y-b9hb8vN_yNJuvc_mey7co4m7SDmOe5AQxCH5CaK447Q
CODEN PNASA6
CitedBy_id crossref_primary_10_1111_j_1432_1033_1995_tb20532_x
crossref_primary_10_1126_scitranslmed_aag2367
crossref_primary_10_1080_07853890802010709
crossref_primary_10_1006_mcpr_2000_0318
crossref_primary_10_1111_j_1365_2362_1994_tb02057_x
crossref_primary_10_1111_j_1399_0004_1992_tb03244_x
crossref_primary_10_1210_clinem_dgae784
crossref_primary_10_1161_01_ATV_17_2_348
crossref_primary_10_1016_S0211_3449_04_70166_6
crossref_primary_10_1093_clinchem_43_6_916
crossref_primary_10_1007_BF00215683
crossref_primary_10_1016_S0021_9150_99_00106_9
crossref_primary_10_1016_S0022_2275_20_43168_2
crossref_primary_10_1177_000456329202900602
crossref_primary_10_1016_S0021_9150_02_00190_9
crossref_primary_10_1016_j_atherosclerosis_2011_12_021
crossref_primary_10_1016_j_ajhg_2012_08_032
crossref_primary_10_1016_j_jacl_2019_10_007
crossref_primary_10_1016_S0021_9150_96_05967_9
crossref_primary_10_1016_S0025_7753_01_71750_2
crossref_primary_10_2217_clp_15_29
crossref_primary_10_12688_f1000research_12938_2
crossref_primary_10_1007_BF02904710
crossref_primary_10_1515_cclm_1991_29_6_395
crossref_primary_10_1093_clinchem_48_4_657
crossref_primary_10_1016_S0021_9258_18_35646_1
crossref_primary_10_12688_f1000research_12938_1
crossref_primary_10_1161_01_ATV_17_4_741
crossref_primary_10_1177_000456329603300508
crossref_primary_10_1016_S0022_2275_20_42783_X
crossref_primary_10_1194_jlr_M400396_JLR200
crossref_primary_10_1038_nrcardio_2011_6
crossref_primary_10_1007_s12041_007_0020_0
crossref_primary_10_1038_sj_ejhg_5200720
crossref_primary_10_1016_j_atherosclerosis_2011_07_106
crossref_primary_10_1146_annurev_genom_083117_021136
crossref_primary_10_1038_nrendo_2010_50
crossref_primary_10_1111_j_1399_0004_1996_tb04333_x
crossref_primary_10_1016_S0021_9258_19_38766_6
crossref_primary_10_1016_S0531_5131_03_00134_1
crossref_primary_10_1002_humu_1380110173
crossref_primary_10_1002__SICI_1098_1004_1996_7_1_70__AID_HUMU12_3_0_CO_2_P
crossref_primary_10_1016_j_mgene_2014_07_006
crossref_primary_10_1016_j_atherosclerosis_2021_02_022
crossref_primary_10_1016_j_jacl_2017_09_003
crossref_primary_10_4158_EP_2_1_37
crossref_primary_10_1016_j_jacl_2017_09_001
crossref_primary_10_1016_j_rec_2020_06_003
crossref_primary_10_1016_S0021_9150_99_00470_0
crossref_primary_10_1016_j_atherosclerosis_2012_05_014
crossref_primary_10_1007_s11886_021_01540_0
crossref_primary_10_1016_S0022_2275_20_37419_8
crossref_primary_10_1006_mcpr_2001_0378
crossref_primary_10_1002_ejlt_200800196
crossref_primary_10_1016_S0022_2275_20_39700_5
crossref_primary_10_1016_S0022_2275_20_41098_3
crossref_primary_10_3109_10408363_2011_565585
crossref_primary_10_1146_annurev_med_042921_112629
crossref_primary_10_2217_clp_09_24
crossref_primary_10_1016_S0022_2275_20_37290_4
crossref_primary_10_1038_ejhg_2015_100
crossref_primary_10_1016_S0021_9150_96_06029_7
crossref_primary_10_1016_S0021_9150_00_00648_1
crossref_primary_10_1161_CIRCRESAHA_114_304801
crossref_primary_10_1093_clinchem_45_7_1094
crossref_primary_10_1016_S1575_0922_05_71016_0
crossref_primary_10_1258_smj_2012_012020
crossref_primary_10_2174_0929867330666230202111849
crossref_primary_10_1006_mgme_1997_2614
crossref_primary_10_1016_j_atherosclerosis_2009_01_004
crossref_primary_10_1016_j_atherosclerosis_2020_02_004
crossref_primary_10_1161_01_ATV_19_3_802
crossref_primary_10_1016_S0300_8932_03_76955_3
crossref_primary_10_1002_gepi_1370120406
crossref_primary_10_3109_07853899009147231
crossref_primary_10_1016_S0022_2275_20_40092_6
crossref_primary_10_1016_j_cell_2019_02_015
crossref_primary_10_3390_nu14071503
crossref_primary_10_1016_S0022_2275_20_33372_1
crossref_primary_10_18311_ajprhc_2018_20031
crossref_primary_10_18087_cardio_2018_11_10195
crossref_primary_10_1146_annurev_genom_082509_141637
crossref_primary_10_1161_CIRCGENETICS_116_001545
crossref_primary_10_3109_07853899009147911
crossref_primary_10_1371_journal_pgen_1008605
crossref_primary_10_1177_0004563219864379
crossref_primary_10_1007_s11427_019_1563_3
crossref_primary_10_1515_CCLM_2003_041
crossref_primary_10_1016_j_atherosclerosis_2004_07_028
crossref_primary_10_1016_S0022_2275_20_42761_0
crossref_primary_10_1046_j_1468_1331_1999_660691_x
crossref_primary_10_1161_CIRCRESAHA_115_306398
crossref_primary_10_1161_circ_106_25_3373
crossref_primary_10_3109_10408363_2011_646942
crossref_primary_10_1172_JCI200318925
crossref_primary_10_1002_humu_1380040308
crossref_primary_10_1101_gr_9_10_936
crossref_primary_10_1016_j_artere_2021_02_002
crossref_primary_10_1016_S0022_2275_20_40088_4
crossref_primary_10_1016_S0009_8981_00_00367_3
crossref_primary_10_1016_S0021_9150_01_00679_7
crossref_primary_10_1016_S0031_3955_16_37021_3
crossref_primary_10_1016_S0021_9258_18_49900_0
crossref_primary_10_1093_eurjpc_zwad018
crossref_primary_10_1111_j_1365_2982_2012_01998_x
crossref_primary_10_1016_j_medcli_2009_03_007
crossref_primary_10_1161_ATVBAHA_117_309326
crossref_primary_10_1016_j_atherosclerosis_2003_11_012
crossref_primary_10_1111_j_1399_0004_1993_tb03890_x
crossref_primary_10_1016_j_cmet_2020_10_020
crossref_primary_10_1016_j_bbalip_2006_03_012
crossref_primary_10_1056_NEJM198906153202407
crossref_primary_10_1007_s11936_000_0010_5
crossref_primary_10_1016_j_atherosclerosis_2011_01_023
crossref_primary_10_1016_S0022_2275_20_41410_5
crossref_primary_10_1016_S0021_9150_99_00481_5
crossref_primary_10_2478_bjmg_2021_0009
crossref_primary_10_1006_geno_1997_4898
crossref_primary_10_1111_j_1749_6632_2002_tb04312_x
crossref_primary_10_1515_CCLM_2000_096
crossref_primary_10_1006_mcpr_1998_0164
crossref_primary_10_1161_01_ATV_15_8_1025
crossref_primary_10_1002__SICI_1098_1004_1997_10_2_160__AID_HUMU8_3_0_CO_2_O
crossref_primary_10_1016_j_jacl_2015_11_013
crossref_primary_10_1194_jlr_R017855
crossref_primary_10_1016_j_jacl_2016_01_009
crossref_primary_10_1586_14779072_1_1_107
crossref_primary_10_1111_j_1365_2362_1995_tb01709_x
crossref_primary_10_1007_BF03216280
crossref_primary_10_1016_j_atherosclerosis_2016_04_011
crossref_primary_10_1136_jmedgenet_2018_105713
crossref_primary_10_1111_j_1365_2796_1992_tb00498_x
crossref_primary_10_3109_00365519509089616
crossref_primary_10_1517_14796678_1_1_17
crossref_primary_10_1016_j_atherosclerosis_2003_12_021
crossref_primary_10_1016_j_atherosclerosis_2014_11_009
crossref_primary_10_1016_j_ejim_2011_01_003
crossref_primary_10_1007_BF01649457
crossref_primary_10_1007_s11883_999_0006_x
crossref_primary_10_1016_0021_9150_96_05912_6
crossref_primary_10_1161_01_ATV_15_7_963
crossref_primary_10_1016_S0022_2275_20_42834_2
crossref_primary_10_1002_jcla_1037
crossref_primary_10_1016_j_bios_2015_05_014
crossref_primary_10_1038_ejhg_2010_94
crossref_primary_10_1002__SICI_1096_8628_19980413_76_5_379__AID_AJMG3_3_0_CO_2_I
crossref_primary_10_1007_s11033_006_9041_7
crossref_primary_10_1016_S1058_9813_03_00049_3
crossref_primary_10_3389_fgene_2020_572045
crossref_primary_10_1515_cclm_1992_30_11_729
crossref_primary_10_1016_S0140_6736_89_92778_5
crossref_primary_10_1016_j_atherosclerosis_2012_07_030
crossref_primary_10_1097_PAT_0b013e32834efa07
crossref_primary_10_1111_j_1399_0004_2007_00915_x
crossref_primary_10_1002_gepi_1370070304
crossref_primary_10_1016_j_ajhg_2023_09_003
crossref_primary_10_1016_S0021_9150_96_05990_4
crossref_primary_10_1016_S0021_9258_19_40266_4
crossref_primary_10_1007_BF00422946
crossref_primary_10_1016_S0022_2275_20_42252_7
crossref_primary_10_1007_BF00215674
crossref_primary_10_1016_j_cell_2012_03_001
crossref_primary_10_1016_j_cca_2008_07_025
crossref_primary_10_36660_abc_20210788
crossref_primary_10_1161_01_ATV_18_11_1780
crossref_primary_10_1016_j_atherosclerosis_2008_10_007
crossref_primary_10_1002__SICI_1098_1004_1996_8_2_168__AID_HUMU9_3_0_CO_2_7
crossref_primary_10_1161_HCG_0000000000000020
crossref_primary_10_1177_019262339001804a12
crossref_primary_10_1186_1471_2350_11_115
crossref_primary_10_1007_s12016_017_8611_x
crossref_primary_10_1038_ng0595_28
crossref_primary_10_1074_jbc_M008890200
crossref_primary_10_1161_01_ATV_17_5_826
crossref_primary_10_1093_clinchem_46_2_224
crossref_primary_10_1111_j_1749_6632_1990_tb42274_x
crossref_primary_10_1016_j_arteri_2020_08_003
crossref_primary_10_1007_s11883_021_00950_3
crossref_primary_10_1161_01_ATV_20_10_e76
crossref_primary_10_1177_153537020422900509
crossref_primary_10_1016_S0022_2275_20_35728_X
crossref_primary_10_1111_j_1365_2796_1992_tb00606_x
crossref_primary_10_1016_j_cca_2005_09_027
crossref_primary_10_1016_S0022_2275_20_42605_7
crossref_primary_10_1007_s10038_003_0010_x
crossref_primary_10_1074_jbc_M413877200
crossref_primary_10_1016_S0021_9258_19_47176_7
crossref_primary_10_1093_hmg_ddq352
crossref_primary_10_1038_s41586_024_08223_0
crossref_primary_10_1111_j_1365_3083_2012_02734_x
crossref_primary_10_1111_j_1365_2362_1991_tb01386_x
crossref_primary_10_1111_j_1749_6632_1990_tb42308_x
crossref_primary_10_1016_S0022_2275_20_41997_2
crossref_primary_10_1016_j_clinbiochem_2007_12_018
crossref_primary_10_1161_01_ATV_15_10_1719
crossref_primary_10_1016_j_jacl_2025_02_006
crossref_primary_10_1016_j_jacl_2016_03_043
crossref_primary_10_1515_cclm_2013_0358
crossref_primary_10_1007_BF01409399
crossref_primary_10_1161_CIRCRESAHA_120_315928
crossref_primary_10_1186_s12881_015_0230_x
crossref_primary_10_1016_0140_6736_91_90920_K
crossref_primary_10_3390_jcm13185615
crossref_primary_10_7554_eLife_74970
crossref_primary_10_1038_s41467_022_33510_7
crossref_primary_10_1093_clinchem_43_9_1630
crossref_primary_10_1093_cvr_cvz032
crossref_primary_10_1111_j_1365_2362_2004_01351_x
crossref_primary_10_1016_j_jacl_2016_09_009
crossref_primary_10_1111_j_1365_2362_2006_01735_x
crossref_primary_10_1111_cge_14453
crossref_primary_10_1016_S0022_2275_20_37702_6
crossref_primary_10_1016_S0021_9258_18_43815_X
crossref_primary_10_1111_j_1365_2362_1995_tb01975_x
crossref_primary_10_1161_CIRCGENETICS_113_000152
crossref_primary_10_1038_nrg_2016_160
crossref_primary_10_1080_10408360500295113
crossref_primary_10_1016_j_bbadis_2014_04_028
crossref_primary_10_1016_j_gene_2012_01_092
crossref_primary_10_1016_S0021_9150_99_00282_8
crossref_primary_10_1093_bmb_lds009
crossref_primary_10_1007_BF01644767
crossref_primary_10_1007_s12291_011_0113_7
crossref_primary_10_1016_S1016_8478_23_13082_2
crossref_primary_10_1373_clinchem_2004_038026
crossref_primary_10_5551_jat_11_131
crossref_primary_10_5858_1999_123_1219_AOOGFI
crossref_primary_10_1016_j_amjcard_2010_01_356
crossref_primary_10_1016_S0022_2275_20_32424_X
crossref_primary_10_3109_07853899209147821
crossref_primary_10_1093_eurheartj_ehs010
crossref_primary_10_1016_S1383_5742_98_00017_9
crossref_primary_10_1038_nature13917
crossref_primary_10_1073_pnas_1100992108
crossref_primary_10_1038_sj_ejhg_5201079
crossref_primary_10_2217_clp_10_63
crossref_primary_10_1093_clinchem_47_3_438
crossref_primary_10_1016_j_tcm_2009_05_001
crossref_primary_10_1002_mgg3_17
crossref_primary_10_1046_j_1365_2362_2001_00915_x
crossref_primary_10_1111_j_1399_0004_1991_tb03024_x
crossref_primary_10_1186_1743_7075_8_23
crossref_primary_10_1016_S0002_9149_98_00849_2
crossref_primary_10_1016_S0021_9150_97_00174_3
crossref_primary_10_1016_S0021_9258_18_49988_7
crossref_primary_10_1161_01_ATV_15_12_2176
crossref_primary_10_1016_S0021_9150_01_00762_6
crossref_primary_10_1056_NEJM199805283382203
crossref_primary_10_3109_07853899209147837
crossref_primary_10_1161_CIRCULATIONAHA_106_661751
crossref_primary_10_1371_journal_pone_0016721
crossref_primary_10_1194_jlr_P023697
crossref_primary_10_1007_BF00577757
crossref_primary_10_1111_j_1399_0004_1993_tb03807_x
crossref_primary_10_1194_jlr_P043182
crossref_primary_10_1007_s11883_008_0030_2
crossref_primary_10_1111_j_1399_0004_1993_tb03821_x
crossref_primary_10_1016_S0095_5108_18_30551_7
crossref_primary_10_1093_clinchem_44_8_1659
crossref_primary_10_1016_S0022_2275_20_32560_8
crossref_primary_10_1038_s10038_017_0347_1
crossref_primary_10_1016_S0022_2275_20_39976_4
crossref_primary_10_1007_s13258_015_0292_3
crossref_primary_10_1016_j_recesp_2020_05_034
crossref_primary_10_1002_mgg3_203
crossref_primary_10_5551_jat_27227
crossref_primary_10_3390_life12060865
crossref_primary_10_1515_CCLM_1998_106
crossref_primary_10_1016_j_abb_2007_11_009
crossref_primary_10_1016_S0022_2275_20_39683_8
crossref_primary_10_1016_j_gene_2014_09_020
crossref_primary_10_1016_S0022_2275_20_41171_X
crossref_primary_10_1038_s41598_019_48402_y
crossref_primary_10_1016_S0021_9258_19_30066_3
crossref_primary_10_1155_2022_7714034
crossref_primary_10_1007_BF00145346
crossref_primary_10_1002_elps_11501401164
crossref_primary_10_1016_S0022_2275_20_41629_3
crossref_primary_10_1111_j_1399_0004_1998_tb02591_x
crossref_primary_10_1016_S0211_3449_08_73234_X
crossref_primary_10_1016_S0022_2275_20_42634_3
crossref_primary_10_1016_S0022_2275_20_40763_1
crossref_primary_10_1016_j_atherosclerosis_2011_02_006
crossref_primary_10_1038_ncpcardio0836
crossref_primary_10_1016_S0009_8981_02_00106_7
crossref_primary_10_1016_S0021_9150_01_00439_7
crossref_primary_10_1023_A_1026704517598
crossref_primary_10_1146_annurev_med_080819_044918
crossref_primary_10_1038_346366a0
crossref_primary_10_1111_j_1526_0968_2004_00143_x
crossref_primary_10_1101_gr_092841_109
crossref_primary_10_1016_j_pharmthera_2014_07_004
crossref_primary_10_1016_S0022_2275_20_39866_7
crossref_primary_10_3389_fcvm_2021_788852
crossref_primary_10_1111_j_1399_0004_1993_tb03883_x
crossref_primary_10_1002_jcla_1860090616
crossref_primary_10_1002_humu_20105
crossref_primary_10_1016_j_ymgme_2008_12_014
crossref_primary_10_1111_j_1399_0004_1998_tb03699_x
crossref_primary_10_1111_j_1365_2796_1992_tb01253_x
crossref_primary_10_1097_01213011_200504000_00005
crossref_primary_10_1586_14737159_7_1_45
crossref_primary_10_1038_aps_2016_134
crossref_primary_10_1210_jc_2007_0221
crossref_primary_10_1007_s00439_007_0448_6
crossref_primary_10_1016_j_atherosclerosis_2021_05_007
crossref_primary_10_1111_joim_13577
crossref_primary_10_17816_MAJ630505
crossref_primary_10_1111_joim_13330
crossref_primary_10_1016_S0022_2275_20_41985_6
crossref_primary_10_1097_CRD_0000000000000384
crossref_primary_10_1016_S0022_2275_20_35115_4
crossref_primary_10_1002_humu_1380020216
crossref_primary_10_1373_clinchem_2006_067645
crossref_primary_10_1034_j_1399_0004_1999_550507_x
crossref_primary_10_1038_ejhg_2013_271
crossref_primary_10_1016_S1016_8478_23_17316_X
crossref_primary_10_1046_j_1365_2362_2003_01094_x
ContentType Journal Article
Copyright 1990 INIST-CNRS
Copyright_xml – notice: 1990 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
8FD
FR3
P64
RC3
7X8
OTOTI
5PM
DOI 10.1073/pnas.86.2.587
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Technology Research Database
Engineering Research Database
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
OSTI.GOV
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Genetics Abstracts
Engineering Research Database
Technology Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList
MEDLINE
Genetics Abstracts



MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Sciences (General)
EISSN 1091-6490
EndPage 591
ExternalDocumentID PMC286517
7018777
2563166
6868848
10_1073_pnas_86_2_587
86_2_587
33170
Genre Research Support, U.S. Gov't, P.H.S
Journal Article
GrantInformation_xml – fundername: NHLBI NIH HHS
  grantid: HL 38781
– fundername: NCRR NIH HHS
  grantid: P41RR01685
GroupedDBID ---
-DZ
-~X
.55
.GJ
0R~
123
29P
2AX
2FS
2WC
3O-
4.4
53G
5RE
5VS
85S
AACGO
AAFWJ
AANCE
ABBHK
ABOCM
ABPLY
ABPPZ
ABTLG
ABXSQ
ABZEH
ACGOD
ACHIC
ACIWK
ACNCT
ACPRK
ADQXQ
ADULT
ADXHL
AENEX
AEUPB
AEXZC
AFFNX
AFOSN
AFRAH
ALMA_UNASSIGNED_HOLDINGS
AQVQM
AS~
CS3
D0L
DCCCD
DIK
DU5
E3Z
EBS
EJD
F5P
FRP
GX1
H13
HGD
HH5
HQ3
HTVGU
HYE
IPSME
JAAYA
JBMMH
JENOY
JHFFW
JKQEH
JLS
JLXEF
JPM
JSG
JST
KQ8
L7B
LU7
MVM
N9A
NEJ
N~3
O9-
OK1
P-O
PNE
PQQKQ
R.V
RHI
RNA
RNS
RPM
RXW
SA0
SJN
TN5
UKR
VOH
W8F
WH7
WHG
WOQ
WOW
X7M
XSW
Y6R
ZCA
ZCG
~02
~KM
-
02
08R
0R
1AW
55
AAPBV
ABFLS
ABPTK
ADACO
ADZLD
AFDAS
AJYGW
AS
ASUFR
DNJUQ
DOOOF
DWIUU
DZ
F20
GJ
JSODD
KM
OHM
PQEST
RHF
VQA
X
XFK
XHC
ZA5
692
6TJ
79B
AAYJJ
AAYXX
ACKIV
AFHIN
AFQQW
BKOMP
CITATION
NHB
TAE
YBH
YKV
YSK
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
VXZ
YIF
YIN
8FD
FR3
P64
RC3
7X8
OTOTI
5PM
ID FETCH-LOGICAL-c604t-61bff033efb3fb69cd55cad01601731c35a624db9ea748af335025d95b852fbd3
ISSN 0027-8424
IngestDate Thu Aug 21 14:13:44 EDT 2025
Fri May 19 01:41:28 EDT 2023
Fri Jul 11 02:03:50 EDT 2025
Fri Jul 11 01:06:05 EDT 2025
Wed Feb 19 02:35:26 EST 2025
Mon Jul 21 09:13:01 EDT 2025
Tue Jul 01 01:21:56 EDT 2025
Thu Apr 24 23:00:11 EDT 2025
Wed Nov 11 00:29:38 EST 2020
Thu May 30 08:50:27 EDT 2019
Thu May 29 08:42:23 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Apolipoprotein B
Human
Allele
Hypercholesterolemia
Nucleotide sequence
Family study
Deficiency
Lipids
Metabolic diseases
Mutation
Haplotype
Aminoacid sequence
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c604t-61bff033efb3fb69cd55cad01601731c35a624db9ea748af335025d95b852fbd3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/286517
PMID 2563166
PQID 15770276
PQPubID 23462
PageCount 5
ParticipantIDs proquest_miscellaneous_15770276
pubmed_primary_2563166
proquest_miscellaneous_78847239
pascalfrancis_primary_6868848
osti_scitechconnect_7018777
pnas_primary_86_2_587_fulltext
crossref_citationtrail_10_1073_pnas_86_2_587
jstor_primary_33170
crossref_primary_10_1073_pnas_86_2_587
pubmedcentral_primary_oai_pubmedcentral_nih_gov_286517
pnas_primary_86_2_587
ProviderPackageCode RNA
PNE
CITATION
AAYXX
PublicationCentury 1900
PublicationDate 1989-01-01
PublicationDateYYYYMMDD 1989-01-01
PublicationDate_xml – month: 01
  year: 1989
  text: 1989-01-01
  day: 01
PublicationDecade 1980
PublicationPlace Washington, DC
PublicationPlace_xml – name: Washington, DC
– name: United States
PublicationTitle Proceedings of the National Academy of Sciences - PNAS
PublicationTitleAlternate Proc Natl Acad Sci U S A
PublicationYear 1989
Publisher National Academy of Sciences of the United States of America
National Acad Sciences
Publisher_xml – name: National Academy of Sciences of the United States of America
– name: National Acad Sciences
SSID ssj0009580
Score 1.8350024
Snippet Familial defective apolipoprotein (apo) B-100 is a genetic disease that leads to hypercholesterolemia and to an increased serum concentration of low density...
SourceID pubmedcentral
osti
proquest
pubmed
pascalfrancis
crossref
pnas
jstor
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 587
SubjectTerms 550401 - Genetics- Tracer Techniques
Alleles
Amino Acid Sequence
Amino acids
APOLIPOPROTEINS
Apolipoproteins B - genetics
Base Sequence
BASIC BIOLOGICAL SCIENCES
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
Biological and medical sciences
BLOOD CHEMISTRY
CHOLESTEROL
Cloning, Molecular
CODONS
DAYS LIVING RADIOISOTOPES
DISEASES
Disorders of blood lipids. Hyperlipoproteinemia
DNA
DNA - genetics
DNA BASE TRANSITIONS
DNA SEQUENCING
ETIOLOGY
Exons
GENE MUTATIONS
Genetic mutation
Genetic Vectors
Genotype
Haplotypes
HEREDITARY DISEASES
Humans
HYDROXY COMPOUNDS
Hyperlipoproteinemia Type II - genetics
ISOTOPES
LIGHT NUCLEI
LIPIDS
LIPOPROTEINS
Lipoproteins, LDL - metabolism
Medical sciences
MEMBRANE PROTEINS
Metabolic diseases
Molecular Sequence Data
Mutation
MUTATIONS
NUCLEI
NUCLEIC ACIDS
ODD-ODD NUCLEI
Oligonucleotides
ORGANIC COMPOUNDS
Pedigree
PHOSPHORUS 32
PHOSPHORUS ISOTOPES
Polymerase chain reaction
Polymorphism, Restriction Fragment Length
PROTEINS
RADIOISOTOPES
RECEPTORS
Receptors, LDL - metabolism
RECOMBINANT DNA
STEROIDS
STEROLS
STRUCTURAL CHEMICAL ANALYSIS
Title Association between a Specific Apolipoprotein B Mutation and Familial Defective Apolipoprotein B-100
URI https://www.jstor.org/stable/33170
http://www.pnas.org/content/86/2/587.abstract
https://www.ncbi.nlm.nih.gov/pubmed/2563166
https://www.proquest.com/docview/15770276
https://www.proquest.com/docview/78847239
https://www.osti.gov/biblio/7018777
https://pubmed.ncbi.nlm.nih.gov/PMC286517
Volume 86
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZgvPCC2NhEGRt-QAgUUnJxHOdxQxsVKmWCFvXNspNYVIJ0Wlsh8es5jh0noZ24vESRY8dRzpfjS77zHYSek5KSpGSlLxkrfAJDsi9YpiX38xwgIoiq_55_mNDRjLyfJ_P2j24dXbKWw_znzriS_7EqlIFddZTsP1jW3RQK4BzsC0ewMBz_ysadd-sIV8LTwZOaAOQJnYHhellLMSwq79z7vrHcQr1bXm9t6P3yolTG6201AO8ZdGevV260WzXcgkmzmXjWhqZYf7HyfO9q0iY6_ry8MczccUsnHm-KHwvDL2vDJFrO0OiTS_31pTRbwO9snEQhHBXL7VQ0kQMwIhITM914XyuEvegsgo0rTexAbEblxOT02nL44KF0luJKrIaMDqOha9UV1p585Jez8ZhPL-bTu-heBCuKqPbhXX1mZqKV7CNaOVa4_ZvezXvTF8NghcF8Ce5Ys2rFCj4sZTKiaLVcaLlr5fI7Abczo5k-RA_sUgSfGVztoztldYD2G-Phl1aR_NUjVHSAhi3QsMAN0HAfN_gcN0DDADTcAA07oG010EA7RLPLi-nbkW_Tc_g5Dcjap6FUKojjUslYSZrlRZIA1LRkYZjGYR4ngkakkFkpUsKEiuMEJthFlkiWREoW8RHaq5ZV-RjhXFJGlJYuFAGRBZUiUFRkQpSFljgTA_S6ees8t9r1OoXKN15zKNKY61fNGeURByMN0AtX_dqIttxW8aA2oasVw3Q6GKBjbVAOc1AtpJxrxlm-5qnOX5lCm5OenV1byihjhA3QYd1HU9z2dbqznCvL8hqgZw1SOPh4_eNOVOVys-JhkqYATHp7jRR6TqM4G6AjgyzXDSxp4pBCU9qDnLuu5eX7V6rF11pmXsesh-mTPz7VMbrffu1P0d76ZlOewEx9LU_rb-wXMhvtyA
linkProvider ABC ChemistRy
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+between+a+specific+apolipoprotein+B+mutation+and+familial+defective+apolipoprotein+B-100&rft.jtitle=Proceedings+of+the+National+Academy+of+Sciences+-+PNAS&rft.au=Soria%2C+L+F&rft.au=Ludwig%2C+E+H&rft.au=Clarke%2C+HRG&rft.au=Vega%2C+G+L&rft.date=1989-01-01&rft.issn=0027-8424&rft.volume=86&rft.issue=2&rft.spage=587&rft.epage=591&rft_id=info:doi/10.1073%2Fpnas.86.2.587&rft.externalDBID=NO_FULL_TEXT
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.pnas.org%2Fcontent%2F86%2F2.cover.gif
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.pnas.org%2Fcontent%2F86%2F2.cover.gif